Use of Cryopreserved Oocytes Increased With Poor Ovarian Response
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 2, 2024 -- Patients with a poor ovarian response (POR) are more likely to return to use previously vitrified oocytes, according to a study published online Jan. 2 in JAMA Network Open.
Yuval Fouks, M.D., M.P.H., from Boston IVF-The Eugin Group in Waltham, Massachusetts, and colleagues examined the association of ovarian response to stimulation and the number of vitrified oocytes with the likelihood and timing of patients returning for oocyte utilization following planned oocyte cryopreservation in a cohort study.
Between 2014 and 2020, 67,893 autologous oocyte freezing cycles were performed in the United States among 47,363 patients. Of these, 13.5 percent were classified as patients with POR, with fewer than five oocytes vitrified across all ovarian stimulation cycles. A total of 2.5 percent of patients returned for oocyte warming and utilization. The researchers found that the rate of return was significantly higher in the POR group than the normal responder group (4.0 versus 2.3 percent). This trend was more pronounced in those aged 30 to 34 years (16.7 versus 8.4 percent for warm cycle versus no warm cycle) and age 35 to 39 years (21.1 versus 14.9 percent). Patients with POR and normal responders had a similar time elapsed from vitrification to warming. In multivariable analysis, having fewer than five oocytes vitrified was associated with increased odds of utilizing oocytes (odds ratio, 1.52).
"Comprehensive counseling should ensure that patients are well-versed with the distinct utilization patterns across different ovarian response groups," the authors write. "Equipped with this knowledge, they can make decisions in line with their reproductive goals and prospective scenario."
One author disclosed ties to Igenomix.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-03 00:15
Read more
- New Drug Regimen Extends Survival for Cervical Cancer Patients
- Female Pediatricians Earn About 93 Percent of Male Pediatricians
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
- JAMA Oncology Publishes Phase 1b/2 Study Data on IASO Bio's Equecabtagene Autoleucel (Fucaso™) in the Treatment of Relapsed/Refractory Multiple Myeloma
- Election Fears Are Keeping Americans Awake at Night, Survey Shows
- Too Much Sitting Harms the Heart, Even in Folks Who Exercise
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions